HealthRx.com

Drake and GLP-1: The Documented Public Record

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Drake and GLP-1: The Documented Public Record
Clinical image for Drake and GLP-1: The Documented Public Record Image: HealthRX.com clinical image

What Drake Has Actually Said

In 2023, Drake referenced Ozempic use in social media posts, treating the topic with a casual tone rather than a formal medical disclosure. The posts did not detail dosing, duration, or prescribing context. He did not name a prescribing physician or clinic, and he has not (as of this writing) given a long-form interview elaborating on his experience with the medication.

That candor, even in its brevity, was notable. At the time, public GLP-1 disclosures skewed heavily toward women. Figures like Chelsea Handler and Sharon Osbourne had already discussed their experiences in televised interviews. Drake's confirmation opened a different conversation: GLP-1 use among men who are not clinically obese but are interested in body composition optimization.

No additional public statements from Drake about GLP-1 medications have surfaced since those 2023 posts. Anything beyond what he posted directly remains speculation.

The Visible Timeline

Media coverage and public appearances document a visible shift in Drake's physique between 2022 and 2024. Mainstream outlets noted a leaner facial appearance and reduced midsection fullness during concert footage and public events in late 2022 and into 2023. These observations predate and overlap with his Ozempic confirmation.

The HealthRX.com Medical Team notes that visible changes of this kind are consistent with semaglutide's documented effects on body composition. A reduction in facial subcutaneous fat, sometimes called "Ozempic face" in popular media, is a recognized clinical phenomenon tied to rapid fat loss rather than to the drug's mechanism itself. Any caloric deficit sustained long enough will reduce facial fat stores. Semaglutide simply makes that deficit easier to maintain through appetite suppression.

It is not possible to attribute Drake's physical changes solely to Ozempic based on public information. Training regimen changes, dietary shifts, and other factors could contribute. He has not publicly clarified the relative role of medication versus lifestyle modification.

What Is Ozempic, Clinically

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes management. Semaglutide mimics the incretin hormone GLP-1, which is released by the gut after eating. It binds to GLP-1 receptors in the pancreas (stimulating insulin secretion), the stomach (slowing gastric emptying), and the brain (reducing appetite signaling in the hypothalamus).

The FDA-approved dose range for Ozempic spans 0.25 mg to 2 mg administered subcutaneously once weekly. Prescribers typically start at 0.25 mg for four weeks, escalate to 0.5 mg, and may increase to 1 mg or 2 mg depending on glycemic response and tolerability. The higher-dose formulation of semaglutide, marketed as Wegovy (up to 2.4 mg weekly), carries a separate FDA approval specifically for chronic weight management.

The STEP trial program demonstrated that semaglutide 2.4 mg produced a mean body weight reduction of 14.9% over 68 weeks versus 2.4% with placebo. In the STEP 1 trial, 86.4% of participants achieved at least 5% weight loss. These results established semaglutide as the most effective single-agent pharmacotherapy for obesity at the time of publication.

GLP-1 Pharmacology in Male Patients

Most large GLP-1 trials enrolled mixed-sex cohorts, but sex-stratified analyses reveal some differences worth noting. Men tend to carry more visceral adipose tissue than premenopausal women, and visceral fat appears particularly responsive to GLP-1 receptor agonist therapy. A sub-analysis from the STEP trials showed that male participants lost a comparable percentage of body weight to female participants, though absolute fat mass reduction was often greater in men due to higher baseline fat mass.

Testosterone levels are also relevant. Obesity in men is associated with lower total and free testosterone through increased aromatase activity in adipose tissue, which converts testosterone to estradiol. Weight loss of 10% or more can partially reverse this suppression, raising total testosterone by 2 to 3 nmol/L on average. For men using GLP-1 medications who achieve significant fat loss, improved hormonal profiles are a plausible secondary benefit, though semaglutide has no direct effect on the hypothalamic-pituitary-gonadal axis.

The HealthRX.com Medical Team considers this an underreported dimension of GLP-1 therapy in men. Weight loss driven by semaglutide may improve testosterone, insulin sensitivity, and cardiovascular risk markers simultaneously, a cluster effect supported by cardiometabolic data from the SELECT trial showing a 20% reduction in major adverse cardiovascular events.

Side Effect Profile and What Men Should Know

The most common adverse effects of semaglutide are gastrointestinal: nausea (affecting roughly 44% of patients at the 2.4 mg dose in STEP 1), diarrhea, vomiting, and constipation. These effects are dose-dependent and typically most pronounced during the escalation phase. Slow titration reduces their severity.

Lean mass loss is a legitimate clinical concern. In the STEP 1 trial, approximately 39% of total weight lost was lean body mass, a ratio comparable to other caloric-restriction interventions but concerning for men interested in preserving muscle. Resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) are the primary countermeasures recommended by endocrine and obesity medicine guidelines.

Rare but serious risks include pancreatitis, gallbladder disease (accelerated by rapid weight loss), and a theoretical concern about medullary thyroid carcinoma based on rodent studies. The FDA label carries a boxed warning for thyroid C-cell tumors, though no causal link has been established in human data.

Why Drake's Disclosure Matters Beyond Celebrity Gossip

Before Drake's confirmation, GLP-1 discourse in popular culture was dominated by women's stories. The medications were sometimes framed as a "Hollywood diet secret" or coded as a vanity tool. Male celebrities largely stayed silent, even as prescribing data showed men made up a growing share of GLP-1 patients.

Drake's casual acknowledgment did two things. First, it normalized the idea that men use these medications. Second, by not treating it as a confession or controversy, he framed GLP-1 use as unremarkable, closer to how someone might mention a supplement or training protocol.

The HealthRX.com Medical Team sees clinical value in that normalization. Stigma around weight management medication discourages men from seeking treatment for obesity and its comorbidities. Data from the CDC show that 41.9% of U.S. adults meet criteria for obesity, with men and women affected at comparable rates. Yet men are less likely to discuss weight management with a physician and less likely to be prescribed pharmacotherapy for it. Public disclosures from male figures, even informal ones, can shift that dynamic.

What Remains Unconfirmed

Several details about Drake's GLP-1 use have not been publicly confirmed:

  • The specific indication (weight management, metabolic health, or another clinical reason)
  • Whether he was prescribed Ozempic (semaglutide 0.5 to 2 mg, FDA-approved for diabetes) or Wegovy (semaglutide up to 2.4 mg, FDA-approved for weight management)
  • Duration of use and whether he continues on the medication
  • Whether he used compounded semaglutide or the brand-name product
  • His prescribing physician or clinical context

Any claims about these specifics circulating online are speculation. The HealthRX.com Medical Team recommends treating unverified details with appropriate skepticism.

At a glance

  • Status: Drake confirmed Ozempic use in 2023 social media posts
  • Drug: Semaglutide (brand name Ozempic), a GLP-1 receptor agonist
  • What's confirmed: Medication use, visible body composition changes 2022-2024
  • What's not confirmed: Dosing, duration, prescribing indication, current status
  • Clinical significance: Among the first male celebrities to publicly confirm GLP-1 use
  • Key trial data: Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks (STEP 1)

Frequently asked questions

›
›
›
›
›

References

Take Our Free 2-min Assessment
Start now